Case Reports

Dexamethasone-associated posterior reversible encephalopathy syndrome


 

Posterior reversible encephalopathy syndrome (PRES) can be correlated with medical illness, hypertension, and treatment with medications that cause immunosuppression. This syndrome was first described by Hinchey and colleagues in 1996. PRES is not necessarily confined to the posterior white matter of the brain as the name indicates, but can be located in the frontal lobes, basal ganglia, cortex, and brain stem. Manifestations of this syndrome include seizures, headache, visual loss, altered mental status, visual changes, and radiologic alterations, and are easily detected on magnetic-resonance imaging (MRI) of the brain.
Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Investigational CDK4/6 inhibitor shows activity, less toxicity
MDedge Hematology and Oncology
Early results positive for treating high-grade gliomas with virus-based therapy
MDedge Hematology and Oncology
Adjuvant temozolomide increases survival in rare anaplastic glioma
MDedge Hematology and Oncology
IL-2 adds only toxicity to neuroblastoma antibody tx
MDedge Hematology and Oncology
Tandem beats single ASCT for childhood neuroblastoma
MDedge Hematology and Oncology
Temozolomide + RT boosts survival in elderly with glioblastoma
MDedge Hematology and Oncology
Childhood cancer survivors face several long-term risks
MDedge Hematology and Oncology
Heat shock protein peptide vaccine appears safe, effective for glioblastoma patients
MDedge Hematology and Oncology
FDA reports shortage of doxorubicin for injection, initiates importation
MDedge Hematology and Oncology
Less cognitive decline with stereotactic radiosurgery after brain metastases resection
MDedge Hematology and Oncology